Page 1 | Search Results | Blood | American Society of Hematology

1-6 of 6

Sort by

Sort Order Select

Journal Articles

REGN5458, a Bispecific BCMAxCD3 T Cell Engaging Antibody, Demonstrates Robust In Vitro and In Vivo Anti-Tumor Efficacy in Multiple Myeloma Models, Comparable to That of BCMA CAR T Cells

David J Dilillo, PhD, Kara Olson, MS, Katja Mohrs, T. Craig Meagher, PhD, Kevin Bray, PhD, Olga Sineshchekova, Thomas Startz, Marc Retter, PhD, Stephen Godin, PhD, Frank Delfino, PhD, John Lin, PhD, Eric Smith, PhD, Olin Gavin Thurston, PhD, Jessica R. Kirshner, PhD

Blood (2018) 132 (Supplement 1): 1944.

https://doi.org/10.1182/blood-2018-99-112500

Published: 2018

Journal Articles

CD20xCD3 Bispecific Fully Human Antibody Induces Potent Anti-Tumor Activity Against CD20-Expressing Tumors in Immune Competent Mice Humanized for CD20 and CD3

Bindu Varghese, PhD, Jayanthi Menon, Luis Rodriguez, Kara Olson, Pamela Krueger, Tammy Huang, PhD, Eric Smith, PhD, Gavin Thurston, PhD, Jessica R. Kirshner, PhD

Blood (2015) 126 (23): 818.

https://doi.org/10.1182/blood.V126.23.818.818

Published: 2015

Journal Articles

A Novel CD20xCD3 Bispecific Fully Human Antibody Induces Potent Anti-Tumor Effects Against B Cell Lymphoma in Mice

Bindu Varghese, PhD, Jayanthi Menon, Luis Rodriguez, Lauric Haber, Kara Olson, Paurene Duramad, PhD, Adelekan Oyejide, Eric Smith, PhD, Gavin Thurston, PhD, Jessica Kirshner, PhD

Blood (2014) 124 (21): 4501.

https://doi.org/10.1182/blood.V124.21.4501.4501

Published: 2014

Journal Articles

Treatment of Newly Diagnosed, Inner-City Multiple Myeloma Patients with Low-Dose Thalidomide in Combination with Dexamethasone and Zoledronate: A Phase II Trial.

Uwe Klueppelberg, MD, PhD, Iuliana Shapira, MD, Eric Smith, PhD, Marc Braunstein, BS, David Kahn, MD, Yury Pertsovsky, Olcay Batuman, MD

Blood (2005) 106 (11): 5180.

https://doi.org/10.1182/blood.V106.11.5180.5180

Published: 2005

Journal Articles

Evidence for Clonality in Circulating Endothelial Progenitor Cells in Multiple Myeloma.

Tayfun Ozcelik, MD, Varsha Vakil, Eric Smith, PhD, Marc Braunstein, Justin Maroney, Uwe Klueppelberg, MD PhD, Sevgi Bagislar, Cemaliye Akyerli, Olcay Batuman, MD

Blood (2004) 104 (11): 2357.

https://doi.org/10.1182/blood.V104.11.2357.2357

Published: 2004

Journal Articles

First-Line Treatment of Multiple Myeloma with a Combination of Thalidomide, Dexamethasone, and Zoledronate (TDZ) in an Inner-City Population with High HIV Prevalence.

Uwe Klueppelberg, MD PhD, Eric Smith, PhD, Laurie Chen, MD, Chona M. Aloba, MD, Iuliana Shapira, MD, Mehdi M. Moezi, MD, Olcay Batuman, MD

Blood (2004) 104 (11): 4932.

https://doi.org/10.1182/blood.V104.11.4932.4932

Published: 2004

NARROW

REGN5458, a Bispecific BCMAxCD3 T Cell Engaging Antibody, Demonstrates Robust In Vitro and In Vivo Anti-Tumor Efficacy in Multiple Myeloma Models, Comparable to That of BCMA CAR T Cells

CD20xCD3 Bispecific Fully Human Antibody Induces Potent Anti-Tumor Activity Against CD20-Expressing Tumors in Immune Competent Mice Humanized for CD20 and CD3

A Novel CD20xCD3 Bispecific Fully Human Antibody Induces Potent Anti-Tumor Effects Against B Cell Lymphoma in Mice

Treatment of Newly Diagnosed, Inner-City Multiple Myeloma Patients with Low-Dose Thalidomide in Combination with Dexamethasone and Zoledronate: A Phase II Trial.

Evidence for Clonality in Circulating Endothelial Progenitor Cells in Multiple Myeloma.

First-Line Treatment of Multiple Myeloma with a Combination of Thalidomide, Dexamethasone, and Zoledronate (TDZ) in an Inner-City Population with High HIV Prevalence.

Email alerts

ASH Publications

American Society of Hematology

REGN5458, a Bispecific BCMAxCD3 T Cell Engaging Antibody, Demonstrates Robust In Vitro and In Vivo Anti-Tumor Efficacy in Multiple Myeloma Models, Comparable to That of BCMA CAR T Cells

CD20xCD3 Bispecific Fully Human Antibody Induces Potent Anti-Tumor Activity Against CD20-Expressing Tumors in Immune Competent Mice Humanized for CD20 and CD3

A Novel CD20xCD3 Bispecific Fully Human Antibody Induces Potent Anti-Tumor Effects Against B Cell Lymphoma in Mice

Treatment of Newly Diagnosed, Inner-City Multiple Myeloma Patients with Low-Dose Thalidomide in Combination with Dexamethasone and Zoledronate: A Phase II Trial.

Evidence for Clonality in Circulating Endothelial Progenitor Cells in Multiple Myeloma.

First-Line Treatment of Multiple Myeloma with a Combination of Thalidomide, Dexamethasone, and Zoledronate (TDZ) in an Inner-City Population with High HIV Prevalence.

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only